A patient with progression had a grade 3 lesion with a high-grade ductal carcinoma in situ, potentially suggesting non-BRCA1-mutated TNBC, as BRCA1-positive TNBC typically responds better to platinum agents. The gene discussed is BRCA1; the disease is ductal breast carcinoma in situ.